Pacific Biosciences of California Inc
NASDAQ:PACB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Pacific Biosciences of California Inc
Cash & Cash Equivalents
Pacific Biosciences of California Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pacific Biosciences of California Inc
NASDAQ:PACB
|
Cash & Cash Equivalents
$279.5m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
28%
|
CAGR 10-Years
24%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Cash & Cash Equivalents
$3.3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
15%
|
|
|
Danaher Corp
NYSE:DHR
|
Cash & Cash Equivalents
$5.7B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
24%
|
|
|
Waters Corp
NYSE:WAT
|
Cash & Cash Equivalents
$587.8m
|
CAGR 3-Years
7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
2%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Cash & Cash Equivalents
$1.8B
|
CAGR 3-Years
12%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-1%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Cash & Cash Equivalents
$2B
|
CAGR 3-Years
18%
|
CAGR 5-Years
2%
|
CAGR 10-Years
7%
|
|
Pacific Biosciences of California Inc
Glance View
Pacific Biosciences of California, Inc. engages in the development, manufacture and sale of an integrated platform for genetic analysis. The company is headquartered in Menlo Park, California and currently employs 728 full-time employees. The company went IPO on 2010-10-27. The firm designs, develops and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. The firm has developed its Single Molecule, Real-Time (SMRT) technology, which enables single molecule, real-time detection of nucleic acid sequences, to address many of the limitations of previous sequencing technologies. The Company’s products include Sequel, Sequel II and Sequel IIe instruments and SMRT Cell 8M, which together can sequence up to approximately eight million deoxyribonucleic acid (DNA) molecules simultaneously, and the previous generation Sequel instrument and Sequel SMRT Cell 1M, which together conduct, monitor, and analyze single molecule biochemical reactions in real time. The firm's Sequel IIe System increases computational capacity and is designed to enable customers to generate PacBio HiFi reads.
See Also
What is Pacific Biosciences of California Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
279.5m
USD
Based on the financial report for Dec 31, 2025, Pacific Biosciences of California Inc's Cash & Cash Equivalents amounts to 279.5m USD.
What is Pacific Biosciences of California Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
24%
Over the last year, the Cash & Cash Equivalents growth was -28%. The average annual Cash & Cash Equivalents growth rates for Pacific Biosciences of California Inc have been -5% over the past three years , 28% over the past five years , and 24% over the past ten years .
